THE YEAR IN REVIEW

“2024 was a year of progress for our Group, following on from the acute challenges we faced in 2023. We returned the Group to a positive full year trading performance, completed the successful divestment of our loss-making retail & pharmacy stocktaking brand, Orridge, and continued with our plans to evolve our International brokerage business into a multi-sector offering with the launch of Healthcare in France, having launched the same sector in Germany in 2023. Demand for our services and pipelines remains robust and the Group is well placed to deliver on its plans for the year ahead.”